Karen L. Reckamp
A5051283101- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Inflammatory mediators and NSAID effects
- Cancer Mechanisms and Therapy
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- SARS-CoV-2 and COVID-19 Research
- Immune cells in cancer
- Cancer survivorship and care
- Cytokine Signaling Pathways and Interactions
- COVID-19 and healthcare impacts
- Palliative Care and End-of-Life Issues
Cedars-Sinai Medical Center
2012-2025
Faculty of 1000 (United States)
2023
Molecular Oncology (United States)
2023
RELX Group (United States)
2023
City of Hope
2013-2022
City Of Hope National Medical Center
2012-2021
University of California, Los Angeles
2005-2018
Amgen (United States)
2006-2018
Pfizer (United States)
2018
Novartis (Germany)
2018
Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared docetaxel in this patient population.We randomly assigned 272 patients to receive at dose mg per kilogram body weight every 2...
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies metastatic NSCLC, because therapeutic recommendations are rapidly changing disease. For example, new were added atezolizumab, ceritinib, osimertinib, pembrolizumab 2017 updates.
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates in immunotherapy. For the 2020 update, systemic therapy regimens have been categorized using a new preference stratification system; certain are now recommended as "preferred interventions," whereas others either "other interventions" or "useful under circumstances."
Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies previously treated patients advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous 057; NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results, including pooled analysis of the studies. Methods Patients stage IIIB/IV (N = 272) 582) NSCLC and disease progression during after prior platinum-based...
RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with fusion-positive NSCLC, the efficacy and safety selective inhibition unknown.We enrolled advanced NSCLC who had previously received platinum-based chemotherapy those were untreated separately a phase 1-2 trial selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by independent review committee. Secondary points included duration...
Abstract Naturally occurring CD4+CD25+ regulatory T cells (T reg) are pivotal in suppressing immune responses and maintaining tolerance. The identification of molecules controlling reg differentiation function is important understanding host malignancy autoimmunity. In this study we show that PGE2 enhances the vitro inhibitory human purified cells. Moreover, induces a phenotype CD4+CD25− PGE2-treated cell-mediated inhibition anti-CD3-stimulated lymphocyte proliferation did not require cell...
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational next-generation ALK inhibitor, in crizotinib-refractory ALK-positive NSCLC. Patients and Methods were stratified by brain metastases best response to crizotinib. They randomly assigned (1:1) oral brigatinib 90 mg once daily (arm A) or 180 a 7-day...
Abstract Cyclooxygenase (COX)-2 and its product prostaglandin (PG) E2 underlie an immunosuppressive network that is important in the pathogenesis of non–small cell lung cancer. CD4+CD25+ T regulatory (Treg) cells play role maintenance immunologic self-tolerance. Treg activities increase cancer appear to a suppressing antitumor immune responses. Definition pathways controlling will enhance our understanding limitation host Tumor-derived COX-2/PGE2 induced expression cell-specific...
Abstract Purpose: Complete and timely tissue genotyping is challenging, leading to significant numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) being undergenotyped for all eight genomic biomarkers recommended by professional guidelines. We aimed demonstrate noninferiority comprehensive cell-free DNA (cfDNA) relative physician discretion standard-of-care (SOC) identify guideline-recommended in mNSCLC. Patients Methods: Prospectively enrolled previously...
Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody immune cell-directing activity, binds each receptor's extracellular domain, bypassing at the inhibitor binding site.CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included population EGFR Exon20ins NSCLC. The primary end...
These NCCN Guidelines Insights focus on recent updates to the 2015 for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it important test tumor tissue from determine whether they alterations that make them candidates therapies. describe different testing methods currently available determining 2 most commonly actionable alterations, notably anaplastic lymphoma kinase (ALK) gene...
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management NSCLC. These Insights focus on recent updates to the targeted therapy and immunotherapy sections in Guidelines. For 2018 update, a new section biomarkers was added.
These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was subject a major update in 2013 Clinical Practice Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The updates and discuss new greater detail.
These NCCN Guidelines Insights focus on recent updates in the 2016 for Non–Small Cell Lung Cancer (NSCLC; Versions 1–4). will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, patients with metastatic NSCLC. For update, panel recommends immune checkpoint inhibitors preferred agents (in absence of contraindications) second-line beyond (subsequent) therapy NSCLC (both squamous nonsquamous histologies). Nivolumab pembrolizumab are based improved overall survival rates,...
Approximately 3% to 10% of EGFR (epidermal growth factor receptor) -mutant non-small cell lung cancers (NSCLCs) undergo transformation small-cell cancer (SCLC), but their clinical course is poorly characterized.We retrospectively identified patients with EGFR-mutant SCLC and other high-grade neuroendocrine carcinomas seen at our eight institutions. Demographics, disease features, outcomes were analyzed.We included 67 patients-38 women 29 men; mutations exon 19 deletion (69%), L858R (25%),...
Most patients with non–small cell lung cancer (NSCLC) are diagnosed advanced cancer. These guidelines only include information about stage IV NSCLC. Patients widespread metastatic disease (stage IV) candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify before initiating aggressive treatment, thus sparing these from unnecessary futile If discovered during surgery, then extensive surgery often aborted. Decisions treatment should be based on...
In approximately 60% of patients with NSCLC who are receiving EGFR tyrosine kinase inhibitors, resistance develops through the acquisition T790M mutation. We aimed to demonstrate that a highly sensitive and quantitative next-generation sequencing analysis mutations from urine plasma specimens is feasible.Short footprint mutation enrichment assays were used interrogate activating in or enrolled TIGER-X (NCT01526928), phase 1/2 clinical study rociletinib previously treated mutant-positive...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on principles of radiation therapy (RT), which include following: (1) general early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, normal tissue dose constraints advanced/palliative RT; (3) RT simulation, planning, delivery. Treatment recommendations should be made by a multidisciplinary team, including...
Abstract Purpose: A phase I study was conducted to determine safety, clinical efficacy, and antitumor immune responses in patients with advanced non–small cell lung carcinoma (NSCLC) following intratumoral administration of autologous dendritic cells (DC) transduced an adenoviral (Ad) vector expressing the CCL21 gene (Ad-CCL21-DC). We evaluated safety tumor antigen–specific situ vaccination (ClinicalTrials.gov: NCT01574222). Experimental Design: Sixteen stage IIIB/IV NSCLC subjects received...
Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) phase I studies. These combinations were evaluated a global III trial.
Purpose: Evaluate safety and determine the recommended phase II dose (RP2D) of ensartinib (X-396), a potent anaplastic lymphoma kinase (ALK) tyrosine inhibitor (TKI), evaluate preliminary pharmacokinetics antitumor activity in first-in-human, I/II clinical trial primarily patients with non-small cell lung cancer (NSCLC).Patients Methods: In escalation, was administered at doses 25 to 250 mg once daily advanced solid tumors; expansion, ALK-positive NSCLC were 225 daily. Patients who had...
PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor has yielded promising results multiple tumor types. METHODS In this randomized phase II Lung-MAP nonmatch substudy (S1800A), patients ineligible for biomarker-matched NSCLC previously treated and platinum-based chemotherapy progressive disease at least 84 days after initiation of were...
Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking genetic alterations detected circulating tumor DNA (ctDNA) can be an informative strategy to identify response and resistance. This study evaluated the utility analyzing ctDNA as a function ensartinib, potent second-generation TKI.Pre-treatment plasma was collected from 76 NSCLC who were TKI-naive or had received prior...